A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

March 31, 2024

Study Completion Date

April 30, 2024

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Tiotropium Bromide Inhalation Powder

It's a generic product of Spiriva HandiHaler.

DRUG

Spiriva HandiHaler

Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.

Trial Locations (1)

450003

Henan (Zhengzhou) Zhonghui Cardiovascular Hospital, Zhengzhou

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY